Generics Bulletin Explains: Removing Interchangeability Information From US Biosimilar Labels

Biosimilars Industry Backs Latest FDA Labeling Guidance – But Originators Disagree

 
• By David Wallace
  
Tug Of War In Silhouette - Fighting Over Chasm, Divide
The off-patent and brand industries are split over US biosimilar labeling • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products